ROS1-Targeted Treatments in NSCLC: Updates and Best Practices for Managed Care
English
Recorded Courses
hosted by Pharmacy Times Continuing Education (PTCE)
hosted by Pharmacy Times Continuing Education (PTCE)
attend it anywhere online
category
Medicine
Oncology
price
Free
ROS1-Targeted Treatments in NSCLC: Updates and Best Practices for Managed Care is organized by Pharmacy Times Continuing Education (PTCE),Release date: October 21, 2022,Expiration date: October 21, 2023,Description:,For multiple types of cancers, identification of biomarkers has an important role in determining treatment approach. ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) rearrangements are observed in up to 2% of non-small cell lung cancers (NSCLCs) and generally are associated with a younger age and little to no history of smoking. Several tyrosine kinase inhibitors (TKIs) are approved or under investigation for treatment of patients with ROS1-rearranged NSCLC. Due to occurrence of resistance mechanisms, ROS1 TKI treatment strategies can be challenging to manage. Managed care professionals involved in the care of patients with ROS1-rearranged NSCLC must understand the latest clinical efficacy data, safety concerns, and how to monitor and address acquired TKI resistance to define best practices for molecular testing and utilization of targeted therapies in specific target populations. This program will focus on the latest developments in molecular testing as related to the use of targeted TKIs in the treatment of ROS1-rearranged NSCLC.,Educational Objectives:,At the completion of this activity, participants will be able to:,• Examine molecular testing and current treatment guidelines for ROS1-rearranged non-small cell lung cancer (NSCLC).,• Differentiate among available and emerging tyrosine kinase inhibitors (TKIs) and the factors affecting treatment selection in the management of ROS1-rearranged NSCLC.,• Explore the managed care approaches and best practices in optimizing the value of biomarker testing and treatment selection of TKIs in the management of ROS1-rearranged NSCLC.